Background
Piramal, a Netherlands-registered pharmaceutical company, entered into a Licence Agreement and Supply Agreement with Brepco, an Irish biotech company, to commercialise Neoatricon®—a paediatric dopamine formulation—across the EU, Norway and UK following its EU marketing approval in May 2024. The agreements contained specific launch timelines: 12 months for Germany, Netherlands and Sweden; 18 months for other territories. Piramal successfully launched in only three countries (Germany, UK, Italy) within the deadlines.
Brepco served two termination notices. The March 2026 notice terminated rights in 25 countries for failure to meet launch deadlines under clause 14.2 of the Licence Agreement. The April 2026 notice purported to terminate all 29 countries on grounds that Piramal had “become insolvent” under clause 14.7.2. Piramal obtained an ex parte interlocutory injunction restraining the March Notice and subsequently amended to include the April Notice.
The Court’s Holding
Justice Eileen Roberts found that Piramal had raised serious issues to be tried on both grounds of termination. On the insolvency claim, the court rejected Brepco’s contentions. Although Piramal had a balance sheet deficit, its audited financial statements showed the parent company (Piramal Pharma) committed to continued funding on a going-concern basis, with long-term intercompany liabilities not due until 2030. Critically, Piramal had the same financial position when the Licence Agreement was executed in 2022 without objection from Brepco, and there was no evidence Piramal had “become” insolvent since then. The court stated: “I am not persuaded that [Piramal’s financial position] would necessarily meet the status of ‘insolvency’ as envisaged in clause 14.7.2.”
Regarding the launch delays, the court found Piramal had failed to meet contractual timelines in 26 of 29 territories but accepted Piramal’s defence that it had adopted a commercially rational “phased” strategy prioritising the EU5 largest markets (Germany, Italy, UK, France, Spain) before expansion. However, the court found Piramal had not clearly identified the specific representation or agreement from Brepco that would modify the express contractual timeframes, noting that Brepco’s contemporaneous correspondence from March 2025 onward repeatedly expressed concern about delays and reasserted its termination rights.
Key Takeaways
- A party cannot rely on an alleged oral or implied variation of express written contract terms unless it can identify precisely what representation was accepted by the other party and how that amended the written agreement.
- Financial deficit alone does not establish insolvency under a commercial contract where auditors confirm going-concern status and parent company support is documented and committed.
- Termination clauses must be interpreted according to their precise wording: here, the “sole cause” exception for supply failures required strict proof that Brepco’s performance was the sole cause of non-launch, which Piramal could not establish.
- For interlocutory injunctions involving commercial exclusive arrangements, courts apply a contextual balance-of-convenience test that weighs whether damages would be an adequate remedy and the risk of injustice to each party.
Why It Matters
This judgment provides important guidance on enforcement of pharmaceutical licensing agreements where exclusivity periods are time-sensitive. The decision reinforces that parties cannot circumvent express contractual deadlines through informal business arrangements or post-hoc claims of altered strategy, even where the underlying commercial rationale is sound. For pharmaceutical companies negotiating exclusive distribution or manufacturing arrangements, it illustrates that a licensor’s explicit reservation of termination rights for non-performance within defined timelines will be enforced strictly: a licensee must either meet the contractual milestones, secure written amendment from the counterparty, or establish that the other party’s material breach prevented compliance.
The insolvency holding is similarly significant: financial distress or balance sheet deficits do not trigger insolvency clauses requiring the licensee to prove actual inability to pay debts as they fall due, particularly where parent company support is documented. This provides important protection to subsidiary entities in pharmaceutical licensing relationships where funding from ultimate parents is standard industry practice.